Recipharm is a Stockholm-founded global contract development and manufacturing organisation (CDMO) with multiple Greater Lisbon sites: the Queluz multi-purpose human/veterinary site, GenIbet biologics in Oeiras (about 70 employees, focused on viral vectors and clinical-trial material), and ReciBioPharm’s Lisbon biologics activities.
Recipharm Queluz is a flexible multi-purpose development and manufacturing site supporting human and veterinary pharmaceutical product manufacturing, with capabilities across liquid, semi-solid and solid dose forms. The acquisition of GenIbet brought Recipharm a specialist Portuguese biologics platform near Lisbon that produces clinical-trial material and viral vectors, both areas where European demand has grown sharply with the cell-and-gene-therapy pipeline.
Inside ReciBioPharm — Recipharm’s dedicated biologics and ATMP arm — Lisbon is one of the named production hubs alongside European peer sites. The Portuguese platform draws on the local talent pool around iBET, the Instituto Gulbenkian de Ciência, and Lisbon’s broader life-sciences ecosystem, which has matured significantly since 2015.
Recipharm is one of the more concrete examples of Nordic capital deepening Portugal’s life-sciences manufacturing base. With EQT and founder Thomas Eldered taking the company private in 2021, the group has continued targeted bolt-on M&A in specialist areas like Portuguese biologics. For Nordic pharma investors looking at Portuguese exposure, Recipharm is the dominant operational case study.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →